Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
- 1Department of Psychiatry, Affiliated Minkang Hospital of Ningbo University (Ningbo Psychiatric Hospital), Ningbo, People's Republic of China.
- 2Health Science Center, Ningbo University, Ningbo, People's Republic of China.
- 3Department of Psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo, People's Republic of China.
Abstract
Post-stroke depression (PSD) is a common neuropsychiatric complication after stroke and has a substantial impact on functional recovery, quality of life, and long-term outcomes. Because stroke-related manifestations, including aphasia, cognitive impairment, fatigue, and somatic symptoms, overlap with depressive symptoms, the clinical identification of PSD still largely relies on symptom assessment and clinical interviews, resulting in delayed diagnosis and intervention in some patients. Recent studies indicate that the development of PSD is not driven by a single pathological process but involves multiple mechanisms, including neuroinflammation, neural network alterations, dysfunction of the neurovascular unit, disturbances in energy and lipid metabolism, imbalance of the microbiota-gut-brain axis, and psychosocial factors following brain injury. The advancement of multi-omics technologies has provided new approaches for investigating the biological mechanisms underlying PSD. This review systematically summarizes recent progress in the application of multi-omics approaches in PSD research, focusing on molecular alterations identified across different omics platforms and potential biomarkers. Furthermore, the role of the hypothalamic-pituitary-adrenal (HPA) axis in stress response regulation and PSD development is discussed within the context of neuro-immune-metabolic interactions. Overall, multi-omics studies have provided new insights into the molecular basis of PSD and facilitated the identification of potential biomarkers and therapeutic targets. However, their clinical utility requires further evaluation through standardized cohorts and validation studies.
Related
- Recent advances in Alzheimer’s disease: From molecular mechanisms to therapeutic strategies
- Molecular Mechanisms and Therapeutic Advances in KRAS G12C‐Mutant Non‐Small Cell Lung Cancer: Toward Mechanism‐Guided Longitudinal Management
- Lactylation in liver fibrosis: from molecular mechanisms to targeted therapeutic strategies
- Molecular mechanisms for sustaining cancer stem cells characteristics and targeted therapeutic strategies
- Myocardial Ischemia-Reperfusion Injury: Molecular Mechanisms and Innovative Therapeutic Strategies
BibTeX
@article{feng2026advances,
title = {{Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.}},
author = {Guoxun Feng and Lei Gao and Yuanzhi Zhao and Zhaoying Yu and Mei Yang and Yaping Chen and Xing Xu},
journal = {Neuropsychiatric disease and treatment},
year = {2026},
month = oct,
doi = {10.2147/ndt.s649205},
url = {https://europepmc.org/article/MED/42953433},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Advances in Multi-Omics Research on Post-Stroke Depression: From Molecular Mechanisms to Therapeutic Strategies.
AU - Guoxun Feng
AU - Lei Gao
AU - Yuanzhi Zhao
AU - Zhaoying Yu
AU - Mei Yang
AU - Yaping Chen
AU - Xing Xu
PY - 2026
DA - 2026/10/24
JO - Neuropsychiatric disease and treatment
DO - 10.2147/ndt.s649205
UR - https://europepmc.org/article/MED/42953433
AB - Post-stroke depression (PSD) is a common neuropsychiatric complication after stroke and has a substantial impact on functional recovery, quality of life, and long-term outcomes. Because stroke-related manifestations, including aphasia, cognitive impairment, fatigue, and somatic symptoms, overlap with depressive symptoms, the clinical identification of PSD still largely relies on symptom assessment and clinical interviews, resulting in delayed diagnosis and intervention in some patients. Recent studies indicate that the development of PSD is not driven by a single pathological process but involves multiple mechanisms, including neuroinflammation, neural network alterations, dysfunction of the neurovascular unit, disturbances in energy and lipid metabolism, imbalance of the microbiota-gut-brain axis, and psychosocial factors following brain injury. The advancement of multi-omics technologies has provided new approaches for investigating the biological mechanisms underlying PSD. This review systematically summarizes recent progress in the application of multi-omics approaches in PSD research, focusing on molecular alterations identified across different omics platforms and potential biomarkers. Furthermore, the role of the hypothalamic-pituitary-adrenal (HPA) axis in stress response regulation and PSD development is discussed within the context of neuro-immune-metabolic interactions. Overall, multi-omics studies have provided new insights into the molecular basis of PSD and facilitated the identification of potential biomarkers and therapeutic targets. However, their clinical utility requires further evaluation through standardized cohorts and validation studies.
SN - 1176-6328
SN - 1178-2021
ER -